Sean Laaman
Stock Analyst at Morgan Stanley
(2.51)
# 2,413
Out of 4,996 analysts
10
Total ratings
77.78%
Success rate
7.73%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Overweight | $46 → $50 | $39.04 | +28.07% | 2 | Sep 17, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $85 → $90 | $65.55 | +37.30% | 2 | Aug 18, 2025 | |
| AXSM Axsome Therapeutics | Assumes: Overweight | $190 | $116.76 | +62.73% | 1 | Jul 3, 2025 | |
| CERT Certara | Assumes: Equal-Weight | $16 | $11.80 | +35.59% | 1 | Jul 3, 2025 | |
| ONC BeOne Medicines AG | Maintains: Overweight | $313 → $330 | $326.06 | +1.21% | 1 | Jun 27, 2025 | |
| ALEC Alector | Assumes: Underweight | $3 → $1.5 | $3.10 | -51.61% | 1 | Mar 7, 2025 | |
| HALO Halozyme Therapeutics | Assumes: Overweight | $67 | $73.75 | -9.15% | 1 | Feb 14, 2025 | |
| RMD ResMed | Upgrades: Overweight | $169 | $270.27 | -37.47% | 1 | Oct 27, 2023 |
Exelixis
Sep 17, 2025
Maintains: Overweight
Price Target: $46 → $50
Current: $39.04
Upside: +28.07%
Disc Medicine
Aug 18, 2025
Maintains: Overweight
Price Target: $85 → $90
Current: $65.55
Upside: +37.30%
Axsome Therapeutics
Jul 3, 2025
Assumes: Overweight
Price Target: $190
Current: $116.76
Upside: +62.73%
Certara
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $16
Current: $11.80
Upside: +35.59%
BeOne Medicines AG
Jun 27, 2025
Maintains: Overweight
Price Target: $313 → $330
Current: $326.06
Upside: +1.21%
Alector
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $3.10
Upside: -51.61%
Halozyme Therapeutics
Feb 14, 2025
Assumes: Overweight
Price Target: $67
Current: $73.75
Upside: -9.15%
ResMed
Oct 27, 2023
Upgrades: Overweight
Price Target: $169
Current: $270.27
Upside: -37.47%